Vicore Team

Carl-Johan Dalsgaard has been a Venture Partner at HealthCap since 2000, thereby he has served as CEO of several companies in which HealthCap has invested. Prior to that, he has ten years of experience from senior positions within the AstraZeneca Group, such as pre-clinical research director, therapeutic area manager of pain and anesthesia, CEO of Astra Pain Control AB and part of the Group’s research management team.

Shareholdings: 477,981

Options: 100,000

Education: MD from the Karolinska Institute. PhD in neurobiology and post-doc experience from Harvard Medical School. Carl-Johan Dalsgaard has also completed a specialist training in plastic surgery.

Hans Jeppsson has previously worked as a pharmaceutical research analyst at Danske Bank and has experience from the capital market and financing-related questions.

Shareholdings: 5,000

Options: 50,000

Education: M.Sc. in Finance from the University of Gothenburg, School of Business, Economics and Law, and also holds a doctor’s degree in Finance from the same university. After he obtained his doctor’s degree he conducted postdoctoral studies at the UC Berkeley in the US. He also has a background in chemical engineering with a focus on biotechnology from Chalmers University of Technology.

Christian Hall is an IR professional with an extensive experience. He has worked as a senior IR professional since 2012 with a number of companies, including Folksam and Academedia. Before that, Christian worked with equity research on banks and stock brokers. Between 1999 and 2012 he worked for Swedbank in different positions, including Head of Equity Research, Equity Strategist and as head of several sectors.

Shareholdings: –

Options: –

Education: B.Sc, Major in Finance, Stockholm School of Economics.

Christina Johansson has been active in the pharmaceutical industry for 26 years, and has during the last 19 years been directly responsible for strategy and development of  nearly 50 potential drug substances in a number of different areas of disease. This has led to knowledge and experience of all aspects of drug development, focusing on development phases before Phase III.

Shareholdings: –

Options: 50,000

Education: M.Sc. in Pharmacy from Uppsala University. Christina Johansson also holds a doctor’s degree in tumor immunology at the University of Gothenburg.

Nina has more than 15 years experience of working with Communication and Administration in the medical industry.

Shareholding: 14 000
Share option rights: 65 000

Rohit Batta has 18 years of experience as a medical doctor with an extensive background leading medical and clinical development teams whilst developing drugs for rare diseases. His previous roles include Senior Director of Cell and Gene Therapy at GlaxoSmithKline leading the clinical development and defining the clinical strategy for haemoglobinopathy gene therapy medicines. He also led the global medical and late stage clinical development teams to launch the world’s first gene therapy for patients with a paediatric rare disease. Rohit holds an MBBS from Kings College London and is a member of the Royal College of General Practitioners and the Faculty of Pharmaceutical Medicine.

Shareholdings: –

Options: 50,000

Education: MBBS from Kings College London and is a member of the Royal College of General Practitioners and the Faculty of Pharmaceutical Medicine.

Johan Raud has more than 20 years of experience from heading research teams and managing drug discovery projects in both big pharma and startups. Johan gained his MD, PhD and Associate Professorship at Karolinska Institutet and Vanderbilt University.

Shareholdings: 238,991

Options: –

Education: MD PhD from the Karolinska Institute and Vanderbilt university, USA

Mimi Flensburg is an experienced biotech R&D leader with strategic and operational background from managing clinical operations. She has an extensive track record of building successful clinical development platformsto lead drug candidates efficiently through clinical phase I, II and III

International experience from handling global clinical trials and working with pharmaceutical companies, in Denmark, Sweden, Austria, US, UK Israel and Switzerland

Shareholdings:

Options:

Education: DVM, PhD

Johanna has a Ph.D and expertise in pharmaceutical metabolism. She has extensive experience in preclinical interpretation and is responsible for producing and refining the regulatory documentation for C21.

Shareholding: 7 004

Share option rights: 25 000

Education: MSc PhD

Ola is PhD and Assoc. Prof. in Pharmaceutics & Biopharmaceutics and  expert in drug formulation/delivery. He has more than 30 years of experience in drug development e.g. Director of Pharmaceutical R&D at Pharmacia, Astra/AstraZeneca, VP Drug Development and Board member at Biotech Companies and Senior Adviser at Karolinska Institutet Innovation AB. Ola is member of  the Review Panel of the Swedish research council.

Shareholding: 149 326

Share option rights: –

Education: PhD and Assoc. Prof